Key Takeaways
- Portugal cannabis export relies on thorough documentation processes, with INFARMED claiming a median of 12-day processing but operators report delays of up to three months.
- The scrutiny stems from the aftermath of Operation Erva Daninha, which revealed serious documentation fraud, prompting stricter export requirements.
- Germany, Spain, and Denmark are the main markets affected by these delays, as they depend heavily on timely cannabis shipments from Portugal.
- INFARMED has increased its inspection activity, but lacks transparency in processing times, causing questions about its efficiency.
- Buyers should verify supplier qualifications and understand that any application changes can reset processing times, complicating export reliability.
Portugal built its reputation as Europe’s largest medical cannabis exporter on cultivation and processing capacity. That reputation now depends on something less visible: whether a shipment’s paperwork can survive scrutiny. At the PTMC 2026 conference in Lisbon on September 10, INFARMED licensing director Vasco Bettencourt told the room that the median time to issue an import or export certificate has dropped to 12 days under a new national platform. An audience member pushed back immediately, saying operators are still waiting two to three months, compared to roughly 28 hours in Switzerland.
That gap between a regulator’s stated benchmark and an operator’s lived experience is the real story here. Portugal’s cannabis bottleneck was never about the plant. It’s about the evidence trail that now has to accompany every gram of it out the door.
What Did INFARMED Actually Say at PTMC 2026?
Bettencourt’s message centered on a single number: 12 days, the median time INFARMED now takes to issue export and import certificates through its new MDS platform. He framed this as proof that the regulator’s overhaul, built over roughly two and a half years, is working. Alongside Bettencourt, GMP inspector Ana Rita Martins confirmed that oversight has expanded beyond new license applicants to cover established operators as well, a shift she linked to a wave of companies that hadn’t faced a full inspection since the 2021-2022 licensing boom.
Both officials were direct about where the friction actually sits. Traceability gaps, weak waste management records, and thin supplier and customer qualification files, not product quality, are driving the slower renewals and stricter certificate reviews. As Bettencourt put it during the panel, INFARMED has “not encountered real quality problems in Portuguese medical cannabis.” The problem, in his telling, is documentation that hasn’t kept pace with what the regulator now requires.
Why the 12-Day Claim Raises More Questions Than It Answers
A median is a single point on a distribution, and INFARMED has not published the distribution around it. There’s no data on the outstanding backlog, no rejection or cancellation rate, and no separate figures for complete applications versus ones sent back for correction. An operator whose complete file clears in 12 days and one whose incomplete file bounces for months could both be technically consistent with the same median.
That matters because INFARMED’s own September 8 export guidance shows how much can go into a “complete” file. Manufacturers may need to supply certificates of analysis for both finished product and raw material, GACP specifications, process-stage documentation with named control points, subcontractor agreements covering steps like sterilization, and full customer qualification records. Every one of those documents has to be resubmitted with each new export request. Nothing migrates automatically between applications, even for a repeat customer or a previously approved product.
Operators who fall short face a tight clock. Correction requests generally carry a five-business-day response window before the application is cancelled outright, and altering submitted information mid-review can trigger cancellation on its own. For a company managing multiple simultaneous shipments, that’s a lot of moving parts to keep synchronized against a regulator that assesses each file in isolation.
What Triggered This Level of Scrutiny?
The current documentation regime traces back to Operation Erva Daninha, a PolÃcia Judiciária investigation launched in May 2025 that executed more than 64 search warrants and led prosecutors to charge 24 defendants, 13 individuals and 11 companies, with criminal association, aggravated trafficking, money laundering, and document falsification.
The specifics of the fraud explain why INFARMED’s new export instructions look the way they do. According to reporting from Business of Cannabis, the network forged import certificates declaring cannabis bound for the Democratic Republic of Congo, Guinea-Bissau, and Kenya, then rerouted the product into European markets instead. One certificate attributed to a Guinean authority listed an expiry date of February 30, 2024, a date that does not exist on any calendar, and it still cleared. Roughly 5,533 kg was declared for export to Congo across 2024 and 2025 with no matching import recorded on the receiving end, and a 357 kg shipment to Kenya in 2025 was measured against an approved national import quota of just 300 grams.
Those numbers explain why INFARMED now cross-checks destination-country import estimates through the International Narcotics Control Board before issuing a certificate. If the country of origin hasn’t published production estimates, no certificate gets issued at all, regardless of how complete the rest of the file is.
What the Inspection Data Shows
INFARMED’s own published figures back up the claim that scrutiny has genuinely increased, separate from any dispute over certificate timing. The regulator conducted 57 cultivation and manufacturing inspections in 2025, up from 38 in 2024, and had already logged 32 more in the first half of 2026, according to INFARMED’s activity report. That’s a real, measurable expansion of oversight, not just rhetoric from a conference stage.
Export volume, meanwhile, hasn’t slowed. Portugal shipped 79,883 kg of medical cannabis in 2025 and had already reached 66,305 kg by the middle of 2026, putting the country on pace to comfortably beat last year’s total. INFARMED published these figures on August 21, 2026, two weeks after opposition party Iniciativa Liberal publicly pressed the Health Minister over the delay in releasing them. The numbers themselves lined up with Germany’s own import records, suggesting the gap was about timeliness of disclosure rather than accuracy of the data.
How Are These Delays Hitting Germany, Spain, and Denmark?
Portugal doesn’t export in a vacuum. According to INFARMED, the European Union remains its dominant market, with Germany, Spain, and Denmark named as the three leading destinations. Any friction in Portugal’s certificate process doesn’t stay contained within Portuguese borders, it ripples straight into pharmacy shelves and patient supply in those countries.
Germany’s BfArM recorded 55.1 tonnes of medical cannabis imported from Portugal in 2025, plus another 10 tonnes in the first quarter of 2026 alone, confirming just how central the Portugal-to-Germany corridor is to the wider European supply chain. At the same time, Business of Cannabis reported that Canadian flower exports routed through Portugal fell 86.6% from their April 2025 peak, with volume shifting to direct shipment into Germany instead. Some buyers, in other words, are already routing around the Portuguese middle step rather than betting on faster certificates.
Spain and Denmark face a version of the same exposure. Both depend on Portuguese supply reaching them on schedule, and neither has visibility into where a given shipment sits in INFARMED’s review queue. A pharmacy or distributor in Copenhagen or Madrid waiting on a delayed certificate has no more insight into the cause than the exporter does. Industry commentary has already pointed toward the Czech Republic and Malta as jurisdictions absorbing some of the volume that would previously have defaulted to Portugal, though both are still growing from a much smaller base.
What Should Buyers Know About Portugal’s Shipment Risk Right Now?
For anyone sourcing from a Portuguese supplier, the practical risk has shifted upstream, into the paperwork itself. Supplier qualification files, destination-country import quotas, subcontractor documentation, and certificate authenticity now sit directly inside shipment risk, not as background compliance detail but as factors that can delay or cancel a delivery outright.
A buyer’s diligence checklist should now include confirming a supplier’s current standing on INFARMED’s public operator list, asking for that supplier’s actual recent certificate turnaround rather than assuming the 12-day median applies, and understanding that any change to a submitted application, even a minor correction, can restart the clock. None of this eliminates Portugal’s advantages in cultivation and processing capacity. It does mean those advantages come with a documentation dependency that didn’t carry the same weight three years ago.
If INFARMED Claims 12 Days, It Should Publish the Queue
INFARMED may be right that most delays trace back to incomplete applications rather than a genuine backlog. Operators may also be describing a real bottleneck that a single median obscures. Both things can be true at once, and a headline statistic without percentile data, cancellation rates, or a clear definition of when the clock actually starts can’t settle the disagreement either way.
The regulator has framed its new documentation demands as protection for compliant operators against the kind of fraud that triggered Operation Erva Daninha in the first place, and that reasoning holds up. But accountability has to run in both directions. If INFARMED wants operators, and the buyers in Germany, Spain, and Denmark who depend on those operators, to trust a 12-day benchmark, the next step is publishing the underlying queue data rather than a single figure delivered from a conference stage.
Frequently Asked Questions
INFARMED reports a median processing time of 12 days under its new MDS platform. However, operators at PTMC 2026 reported real-world delays of two to three months, and INFARMED has not published data on the full range of processing times.
The stricter rules follow Operation Erva Daninha, a 2025 investigation that uncovered forged import certificates, falsified expiry dates, and export quantities exceeding approved quotas. INFARMED’s September 8 export instructions now require certificates of analysis, GACP specifications, and customer qualification files for every shipment.
Germany, Spain, and Denmark are Portugal’s largest medical cannabis export markets. Germany’s BfArM recorded 55.1 tonnes imported from Portugal in 2025 alone, meaning any delay in Portugal’s certification process poses a direct supply risk for pharmacies and distributors across these markets.
No. INFARMED officials have explicitly stated they have not found quality problems with Portuguese-produced medical cannabis. The scrutiny targets traceability, waste management records, and the qualification of suppliers and customers, not the product itself.
Since Portugal tightened its cannabis export rules in April 2025, the Czech Republic and Malta have emerged as alternative export routes. Canadian flower exports through Portugal have dropped by 86.6%, though both new markets are still small compared to Portugal’s previous export volume.
